Results 71 to 80 of about 18,687 (213)

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir‐based antiretroviral therapy

HIV Medicine, Volume 27, Issue 5, Page 803-808, May 2026.
Abstract Background Darunavir‐based antiretroviral therapy (ART) is commonly used in people with HIV who experience adherence challenges and/or have complex resistance patterns. Changes in ART commissioning have led to an increased use of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in these populations despite limited real‐world outcome ...
Rhianna Sheridan, Yasmin Osei‐Kuffour Ekert, Lucy Campbell, Mark Zuckerman, Sally Hawkins, Kate Childs, Frank A. Post   +6 more
wiley   +1 more source

Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals [PDF]

, 2017
Objectives Darunavir is a protease inhibitor that is administered with low-dose ritonavir to enhance its bioavailability. It is prescribed at standard dosage regimens of 600/100 mg twice daily in treatment-experienced patients and 800/100 mg once daily ...
Aouri, M., Arab-Alameddine, M., Battegay, M., Bernasconi, E., Bucher, H. C., Buclin, T., Böni, J., Bürgisser, P., Calmy, A., Cattacin, S., Cavassini, M., Cavassini, M., Csajka, C., de Tejada, B. M., Dubs, R., Décosterd, L. A., Egger, M., Elzi, L., Fayet-Mello, A., Fischer, M., Flepp, M., Fontana, A., Francioli, P., Furrer, H., Fux, C. A., Gatri, M., Gorgievski, M., Guidi, M., Günthard, H., Hirsch, H. H., Hirschel, B., Hösli, I., Kahlert, C., Kaiser, L., Karrer, U., Kind, C., Klimkait, T., Ledergerber, B., Ledergerber, B., Lubomirov, R., Martinetti, G., Müller, N., Nadal, D., Paccaud, F., Panchaud, A., Pantaleo, G., Rauch, A., Regenass, S., Rentsch, K., Rickenbach, M., Rotger, M., Rudin, C., Schmid, P., Schultze, D., Schüpbach, J., Speck, R., Taffé, P., Telenti, A., Telenti, A., Trkola, A., Vernazza, P., Weber, R., Widmer, N., Yerly, S.   +63 more
core  

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort [PDF]

, 2019
Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected ...
Abeli C., Acinapura R., alungo A., Andreoni M., Angarano G., Antinori A., aracino A., atini A., azzarin A., Bagella P., Bai F., Baldelli F., Baldin G., Balotta C., Bandera A., Barocci V., Bassetti M., Blanc P., Bobbio N., Bonfanti P., Bonora S., Borderi M., Borgia G., Cacopardo B., Calcagno A., Capetti A., Capobianchi M. R., Capozzi M., Caramello P., Carletti F., Carrara S., Cascio A., Cassola G., Castagna A., Castelli F., Castelnuovo F., Cattelan A. M., Cauda R., Ceccherini-Silberstein F., Ceccherini-Silberstein F., Cecchetto M., Celesia B., Chiodera A., Cicalini S., Cingolani A., Cinque P., Colomba C., Costantini A., Cozzi-Lepri A., Cozzi-Lepri A., Cristaudo A., d'Arminio Monforte A., De Luca A., Di Biagio A., Di Caro A., Di Giuli C., Di Martino F., Di Perri G., Esposito V., Fabrizio C., Falasca K., Fanti I., Fontana Del Vecchio R., Francisci D., Galli L., Galli M., Gentile I., Giacometti I. A., Gianotti N., Girardi E., Gori A., Graziano S., Guaraldi G., i V., Iaiani G., Iardino R., Ippolito G., Lapadula G., lessandrini A., Lichtner M., Lo Caputo S., Lorenzini P., Lorenzotti S., Macchia M., Maddaloni L., Madeddu G., Maggiolo F., Maggiolo F., Magnani G., Manfrin V., Marchetti G., Marinello S., Mastrorosa I., Mazzarello G., Menzaghi B., Migliorino C., Milini P., Minardi C., Moioli M. C., Molteni C., Mondi A., Monno L., Mussini C., Nozza S., Nunnari G., ondero A., Orofino G. C., Pan A., Parruti G., Pellicano G., Pellizzer G., Perno C. F., Petrone F., Piolini R., Plazzi M. M., Pozzetto I., Prota G., Puoti M., Puzzolante C., Quartu S., Quiros Roldan E., Rezza G., Ridolfo A. L., Rivano Capparucia M., Rizzardini G., Rodano' A., Rossetti B., Rossotti R., Rusconi S., Rusconi S., Salpietro S., Sangiovanni V., Santoro M. M., Sarmati L., Savinelli S., Schiaroli E., Sciandra M., Segala D., Sighinolfi L., Sozio F., Starnini G., Suardi C., Tavelli A., Tavelli A., Tincati C., Truffa S., Ursitti M. A., Vecchiet J., Vergori A., Verucchi G., Viale P., Vichi F., Viscoli C., Viviani F., von Schloesser F., Vullo V.   +155 more
core   +4 more sources

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study

HIV Research & Clinical Practice, 2019
Background: The once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is approved for the treatment of HIV-1 infection.
Bruce Rashbaum, Christoph D. Spinner, Cheryl McDonald, Cristina Mussini, John Jezorwski, Donghan Luo, Erika Van Landuyt, Kimberley Brown, Eric Y. Wong   +8 more
doaj   +1 more source

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

BMC Infectious Diseases, 2019
Background Direct comparisons between lamivudine plus bPIs and lamivudine plus dolutegravir as maintenance strategies in virologically-suppressed HIV positive patients are lacking.
Alberto Borghetti, Francesca Lombardi, Roberta Gagliardini, Gianmaria Baldin, Arturo Ciccullo, Davide Moschese, Arianna Emiliozzi, Simone Belmonti, Silvia Lamonica, Francesca Montagnani, Elena Visconti, Andrea De Luca, Simona Di Giambenedetto   +12 more
doaj   +1 more source

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir

Therapeutics and Clinical Risk Management, 2009
Michael Neely, Andrea KovacsUniversity of Southern California Keck School of Medicine, Department of Pediatrics, Division of infectious Diseases, Los Angeles, CA, USAAbstract: Darunavir is currently the most recently approved HIV-1 protease inhibitor. It
Michael Neely, Andrea Kovacs
doaj  

Virological efficacy of PI monotherapy for HIV-1 in clinical practice. [PDF]

, 2016
BACKGROUND: Clinical trials of PI monotherapy indicate that most participants maintain viral suppression and emergent protease resistance is rare.
Collier, D, Copas, AJ, El Bouzidi, K, Gupta, RK, Miller, RF, Nastouli, E   +5 more
core   +1 more source

Effectiveness and Persistence of Long‐Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort

Journal of the International AIDS Society, Volume 29, Issue 4, April 2026.
ABSTRACT Introduction Migrants living with HIV often face high mobility, vulnerability and limited baseline information on HIV‐1 genotype or treatment history. We aimed to assess the effectiveness and persistence of long‐acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) among migrants in Spain. Methods This multicentre cohort study across 58
Jara Llenas‐García, María del Mar Arcos Rueda, Ruth Calderón Hernaiz, Roberto Pedrero Tomé, Otilia Bisbal Pardo, Mariano Matarranz, Miguel Torralba, María José Galindo Puerto, Adrián Rodríguez, María Peñaranda Vera, Isabel Sanjoaquín Conde, Sara de la Fuente Moral, Alfonso Cabello‑Úbeda, Carolina Navarro San Francisco, Karenina Antelo Cuéllar, Marc Pedrosa Aragón, María Aguilera García, Juan Tiraboschi, Rosa María Martínez Álvarez, María Jesús Vivancos, Carmen Montero Hernández, Enrique Bernal Morell, Noemí Cabello‐Clotet, Luis Enrique Morano Amado, Laura Gisbert Pérez, María Antonia Sepúlveda, María Remedios Alemán Valls, Antonio Jesús Sánchez Guirao, Chiara Fanciulli, Cristina Escrig, Eva María Ferreira Pasos, Ana Lucas‐Dato, Sara García Torras, Carmen Hidalgo Tenorio, Miriam Estébanez, Magdalena Muelas‑Fernandez, Juan Emilio Losa García, Ana Cerezales Calviño, María Elisa Pino Díaz, Clara Martínez Montes, Víctor Arenas García, Francisco Arnaiz de las Revillas, Hadrián Pernas Pardavila, Sergio Padilla, María Ángeles Garcinuño Jiménez, Lucía Alonso Alonso, Noemí Ramos Vicente, Patricia Noemí Barragán Gallo, Rebeca Cabo Magadan, Míkel del Álamo, Miguel Vicente Egido Murciano, Alberto Juárez Toquero, Alberto Romero Palacios, Marta Clavero Olmos, María del Mar García Navarro, José Sanz, Juan Carlos Gainzarain, Marta Milian Sanz, Beatriz de la Calle, Oscar Luis Ferrero Benéitez, Jesús Troya, Luis Buzón‐Martín, The RELATIVITY Group   +62 more
wiley   +1 more source

Synthesis of Sulfur Enriched Cyclohexenes via the Tungsten‐Promoted Dearomatization of a Phenyl Sulfone

European Journal of Organic Chemistry, Volume 29, Issue 9, 2 March 2026.
A method for synthesizing sulfur‐substituted cyclohexenes is reportedthat leverages the η2‐coordination of a phenyl sulfone to [WTp(NO)(PMe3)] (Tp = trispyrazolylborate). Three sequential protonation and nucleophilic additions to the bound arene, followed by oxidative decomplexation, affords functionalized cyclohexenes bearing sp3‐ and sulfur‐enriched ...
Daniel J. Siela, Matthew C. McGraw, Diane A. Dickie, W. Dean Harman   +3 more
wiley   +1 more source

Effect of particle size on release of solid dispersed particles during the "Dissolution" test

Разработка и регистрация лекарственных средств
Introduction. The use of the solid disperse systems method to increase the solubility of lipophilic active pharmaceutical ingredients is industrially applicable using different technologies, but the influence of particle size on the dissolution of these ...
S. A. Zolotov, A. V. Panov
doaj   +1 more source